hydroxypropyl-beta-cyclodextrin

Hydroxypropyl-beta-cyclodextrin, also known as Hydroxypropyl-beta-cyclodextrin; THPB; HP-beta-CD; HPbCD; HP-beta-CyD; VTS-270; HPbetaCD; HPbetaCyD, is a drug candidate potentially for the treatment of Niemann-Pick type C diseases. In April 2009, hydroxypr

HP-β-CD (HP-β-CD) 是一种药物递送载体，可提高稳定性和利用度。

PX-316 is a AKT inhibior. PX-316, when administered intraperitoneally to mice at 150 mg kg, inhibits Akt activation in HT-29 human tumor xenografts up to 78% at 10 h with recovery to 34% at 48 h. PX-316 has antitumor activity against early human MCF-7 breast cancer and HT-29 colon cancer xenografts in mice. PX-316 formulated in 20% hydroxypropyl-beta-cyclodextrin for intravenous administration is well tolerated in mice and rats with no hemolysis and no hematological toxicity. Thus, PX-316 is the lead compound of a new class of potential agents that inhibit Akt survival signaling.